Interestingly, although it has been shown that 90% of patients with PDAC carry primary KRAS mutations at codons 12, 13 or 61, we identified 9 cfDNA variants outside of the predominantly mutated codons, not reported in the ICGC PDAC database but reported in the COSMIC database for other types of cancer, allowing for an increased sensitivity of 22.5%. Here, KRAS is linked to cancer.